Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG826

—

9050d965-257b-5b24-8cc7-7659a27351a8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.565
  • MYC_TARGETS_V1+0.560
  • OXIDATIVE_PHOSPHORYLATION+0.515
  • E2F_TARGETS+0.497
  • G2M_CHECKPOINT+0.448
  • UNFOLDED_PROTEIN_RESPONSE+0.441
  • DNA_REPAIR+0.340
  • MTORC1_SIGNALING+0.339
  • ALLOGRAFT_REJECTION+0.287
  • FATTY_ACID_METABOLISM+0.178

Top 10 suppressed

  • MYOGENESIS-0.384
  • ESTROGEN_RESPONSE_EARLY-0.349
  • PANCREAS_BETA_CELLS-0.347
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.312
  • UV_RESPONSE_DN-0.296
  • ESTROGEN_RESPONSE_LATE-0.295
  • HEDGEHOG_SIGNALING-0.282
  • HEME_METABOLISM-0.279
  • KRAS_SIGNALING_DN-0.252
  • HYPOXIA-0.248

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR17866823
colon-landscapes@1
——0.851
2MNG266
mng-umap@100
——0.837
3NB4_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
ccle-aml@v2024.1
AML—0.835
4TCGA-AR-A0TU-01A-31R-A109-07
breast-umap@18
—E0.833
5SRR8518360
breast-umap@18
—E0.832
6TCGA-58-8387-01A-11R-2296-07
lung-landscapes@6
—cohortSQ20.829
7C3N-00203
lung-landscapes@6
—cohortA10.828
8TCGA-58-A46M-01A-11R-A24H-07
lung-landscapes@6
—cohortSQ20.825
9MNG277
mng-umap@100
——0.823
10SRR8518323
breast-umap@18
—E0.823

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.565Idelalisib— uncovered
MYC_TARGETS_V10.560Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.515Remibrutinib— uncovered
E2F_TARGETS0.497Inavolisib— uncovered
G2M_CHECKPOINT0.448Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.441Idelalisib— uncovered
DNA_REPAIR0.340Idelalisib— uncovered
MTORC1_SIGNALING0.339Inavolisib— uncovered
ALLOGRAFT_REJECTION0.287Idelalisib— uncovered
FATTY_ACID_METABOLISM0.178Inavolisib— uncovered
MITOTIC_SPINDLE0.146Inavolisib— uncovered
PROTEIN_SECRETION0.143Remibrutinib— uncovered
SPERMATOGENESIS0.131Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.113Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.089Inavolisib— uncovered
P53_PATHWAY0.078Idelalisib— uncovered
GLYCOLYSIS0.061Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.032Idelalisib— uncovered
PEROXISOME0.032Idelalisib— uncovered
ADIPOGENESIS0.023Inavolisib— uncovered